AR035548A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
AR035548A1
AR035548A1 ARP000102709A ARP000102709A AR035548A1 AR 035548 A1 AR035548 A1 AR 035548A1 AR P000102709 A ARP000102709 A AR P000102709A AR P000102709 A ARP000102709 A AR P000102709A AR 035548 A1 AR035548 A1 AR 035548A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroatoms
hydrogen
interrupted
independently hydrogen
Prior art date
Application number
ARP000102709A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10854788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035548(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR035548A1 publication Critical patent/AR035548A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000102709A 1999-06-04 2000-06-01 Compuestos organicos AR035548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9913083.3A GB9913083D0 (en) 1999-06-04 1999-06-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR035548A1 true AR035548A1 (es) 2004-06-16

Family

ID=10854788

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102709A AR035548A1 (es) 1999-06-04 2000-06-01 Compuestos organicos

Country Status (38)

Country Link
US (9) US6878721B1 (forum.php)
EP (2) EP1183240B1 (forum.php)
JP (1) JP3785365B2 (forum.php)
KR (1) KR100718615B1 (forum.php)
CN (1) CN1156451C (forum.php)
AR (1) AR035548A1 (forum.php)
AT (1) ATE440083T1 (forum.php)
AU (1) AU765919B2 (forum.php)
BE (1) BE2010C011I2 (forum.php)
BR (1) BRPI0011324B8 (forum.php)
CA (1) CA2375810C (forum.php)
CO (1) CO5170518A1 (forum.php)
CY (3) CY1109604T1 (forum.php)
CZ (1) CZ302403B6 (forum.php)
DE (2) DE122010000009I2 (forum.php)
DK (2) DK2332915T3 (forum.php)
ES (2) ES2331457T3 (forum.php)
FR (1) FR10C0006I2 (forum.php)
GB (1) GB9913083D0 (forum.php)
HK (1) HK1045837B (forum.php)
HU (1) HU227034B1 (forum.php)
IL (2) IL146578A0 (forum.php)
LU (1) LU91651I2 (forum.php)
MX (1) MXPA01012474A (forum.php)
MY (1) MY126951A (forum.php)
NL (1) NL300437I1 (forum.php)
NO (2) NO322944B1 (forum.php)
NZ (1) NZ515669A (forum.php)
PE (1) PE20010219A1 (forum.php)
PL (1) PL198847B1 (forum.php)
PT (2) PT2332915E (forum.php)
RU (1) RU2244709C2 (forum.php)
SI (1) SI1183240T1 (forum.php)
SK (1) SK287260B6 (forum.php)
TR (1) TR200103497T2 (forum.php)
TW (1) TWI253447B (forum.php)
WO (1) WO2000075114A1 (forum.php)
ZA (1) ZA200109931B (forum.php)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
US6933410B2 (en) * 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (es) * 2003-04-02 2010-06-01 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
KR20060052911A (ko) * 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 베타흥분제와 항콜린제를 포함하는 흡입용 의약품
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1574501A1 (en) * 2004-03-11 2005-09-14 Pfizer Limited Quinolinone derivatives, pharmaceutical compositions containing them and their use
WO2005089718A2 (en) 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
WO2006031556A2 (en) * 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
EP2281813A1 (en) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
BRPI0615064A2 (pt) * 2005-08-26 2011-05-03 Astrazeneca Ab combinação de compostos que pode ser usada no tratamento de doenças respiratórias, especialmente, doença pulmonar obstrutiva crÈnica (dpoc) e asma
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
TWI392493B (zh) * 2005-10-26 2013-04-11 Novartis Ag 格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
CA2654801C (en) * 2006-06-30 2014-08-19 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
US20100239551A1 (en) 2007-02-09 2010-09-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
PT2155721E (pt) 2007-05-07 2011-05-09 Novartis Ag Compostos org?nicos
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
KR20110017456A (ko) 2008-06-18 2011-02-21 아스트라제네카 아베 호흡기 장애의 치료를 위한 베타2-아드레날린성 수용체 효능제로서 작용하는 벤족사지논 유도체
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8362064B2 (en) 2008-12-30 2013-01-29 Pulmagen Theraputics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
TW201040154A (en) * 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (forum.php) 2009-08-20 2015-06-05 Novartis Ag
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
US8877930B2 (en) * 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011102794A1 (en) * 2010-02-18 2011-08-25 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EA022046B1 (ru) 2010-07-14 2015-10-30 Новартис Аг Гетероциклические соединения, агонисты рецептора ip
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CA2814445A1 (en) 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
CN104053659B (zh) 2012-01-13 2016-11-09 诺华股份有限公司 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
CN104169282B (zh) 2012-01-13 2016-04-20 诺华股份有限公司 Ip受体激动剂的盐
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CN103539677B (zh) * 2012-07-16 2015-04-22 武汉万知生物医药有限公司 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP2897937B1 (en) 2012-09-21 2017-12-06 Crystal Pharma S.A.U Process for the preparation of indacaterol and intermediates thereof
WO2014097151A2 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
EP2956455B1 (en) 2013-02-13 2017-05-17 Novartis AG Ip receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
WO2014154841A1 (en) * 2013-03-27 2014-10-02 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
KR20160033726A (ko) 2013-07-18 2016-03-28 노파르티스 아게 헤테로방향족 고리-벤질-아미드-사이클 코어를 포함하는 오토탁신 억제제
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN104744360B (zh) * 2013-12-26 2017-02-22 成都伊诺达博医药科技有限公司 一种合成茚达特罗的新方法
EP3092217B1 (en) 2014-01-09 2020-06-03 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
RU2016141948A (ru) 2014-03-27 2018-04-27 Новартис Аг Высушенные распылением дисперсии твердое-в-масле-в-воде активных фармацевтических ингредиентов для ингаляции
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
CA2945069A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
WO2015162459A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
DE102014217205A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W
DE102014217201A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90
CA2973817A1 (en) 2015-01-20 2016-07-28 Novartis Ag Application unlock using a connected physical device and transfer of data therebetween
CN107735390B (zh) 2015-01-20 2021-06-08 欧伦股份公司 茚满胺衍生物的制备方法和新合成中间体
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
ES2897697T3 (es) 2015-07-03 2022-03-02 Novartis Ag Inhalador adaptado para leer información almacenada en un medio de almacenamiento de datos de un recipiente
ITUB20153978A1 (it) 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
WO2019135101A1 (en) 2018-01-02 2019-07-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
KR102724168B1 (ko) 2018-03-19 2024-11-01 다우 글로벌 테크놀로지스 엘엘씨 폴리올레핀 - 폴리디오르가노실록산 블록 공중합체 및 이의 합성을 위한 방법
CN111741997B (zh) 2018-03-19 2022-08-09 美国陶氏有机硅公司 聚烯烃-聚二有机硅氧烷嵌段共聚物及用于其合成的氢化硅烷化反应方法
CN111868196B (zh) 2018-03-19 2022-08-30 美国陶氏有机硅公司 含有聚烯烃-聚二有机硅氧烷共聚物的聚有机硅氧烷热熔胶组合物和其制备和使用方法
CA3101628A1 (en) 2018-03-19 2019-09-26 Dow Silicones Corporation Hot melt adhesive composition containing a polyolefin - polydiorganoosiloxane copolymer and methods for the preparation and use thereof
JP7334195B2 (ja) 2018-07-17 2023-08-28 ダウ シリコーンズ コーポレーション ポリシロキサン樹脂－ポリオレフィンコポリマー並びにその調製方法及び使用方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US11623924B2 (en) 2018-10-05 2023-04-11 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN109369417B (zh) * 2018-10-19 2021-07-06 诚达药业股份有限公司 一种2-氨基茚满衍生物的制备方法
WO2020105012A1 (en) 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN109896967B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种间二乙氨基苯酚的制备方法
CN109896966B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种n,n-二丁基间氨基苯酚的制备方法
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN110229078A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 一种茚达特罗起始原料开环杂质的制备
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
JP2023520397A (ja) * 2020-04-03 2023-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
MX2023001725A (es) 2020-08-14 2023-02-22 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
CN116963715A (zh) 2020-09-29 2023-10-27 艾罗克斯医疗有限责任公司 茚达特罗的液体配制品
CN115677577B (zh) * 2021-11-03 2024-11-15 中国药科大学 靶向srsf6蛋白的小分子化合物及其制备方法和用途
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN115521254B (zh) * 2022-09-27 2024-05-31 中国药科大学 一种茚达特罗衍生物及其制备方法和应用
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2354959C3 (de) * 1973-11-02 1980-02-07 Dr. Karl Thomae Gmbh, 7950 Biberach Neues Verfahren zur Herstellung von 4-Amino-3,5 dihalogen phenyl-athanolaminen
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JPH0518007A (ja) 1991-07-05 1993-01-26 Konoike Constr Ltd 鉄骨梁との接合部を内蔵したｐｃ柱
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1993018007A1 (en) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
DK0608568T3 (da) * 1993-01-29 1998-09-28 American Cyanamid Co Aminocycloalkanobenzodioxoler som beta 3-selektiveadrenerge midler
JP3342491B2 (ja) * 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
FR2711407B1 (fr) * 1993-10-19 1996-01-26 Allevard Sa Perfectionnements aux barres de torsion métalliques.
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
JP3878210B2 (ja) 1995-02-01 2007-02-07 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
TW375604B (en) * 1996-02-19 1999-12-01 Kissei Pharmaceutical 3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
JP3690071B2 (ja) 1997-06-24 2005-08-31 井関農機株式会社 ロータリ耕耘具の防護装置
WO1999009001A1 (fr) * 1997-08-19 1999-02-25 Kissei Pharmaceutical Co., Ltd. Derives de phenylethanolaminotetraline et bronchodilatateurs
WO1999051564A1 (en) 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
UA72632C2 (uk) 2000-06-27 2005-03-15 Лабораторіос С.А.Л.В.А.Т., С.А. Карбамати, похідні від арилалкіламінів

Also Published As

Publication number Publication date
CZ302403B6 (cs) 2011-05-04
AU765919B2 (en) 2003-10-02
CY2010003I2 (el) 2012-01-25
US20110034509A1 (en) 2011-02-10
US20050153957A1 (en) 2005-07-14
FR10C0006I1 (forum.php) 2010-03-26
US20140343091A1 (en) 2014-11-20
SK17432001A3 (sk) 2002-06-04
US20120302531A1 (en) 2012-11-29
SK287260B6 (sk) 2010-04-07
HUP0201658A3 (en) 2005-01-28
PE20010219A1 (es) 2001-03-21
KR100718615B1 (ko) 2007-05-16
BR0011324B1 (pt) 2014-11-25
TR200103497T2 (tr) 2002-05-21
ES2331457T3 (es) 2010-01-05
SI1183240T1 (sl) 2010-01-29
LU91651I9 (forum.php) 2019-01-03
CN1156451C (zh) 2004-07-07
EP1183240A1 (en) 2002-03-06
EP2332915B1 (en) 2013-02-27
DE60042781D1 (de) 2009-10-01
HK1045837B (en) 2010-03-26
HK1045837A1 (en) 2002-12-13
US7622483B2 (en) 2009-11-24
US8283362B2 (en) 2012-10-09
DK1183240T3 (da) 2009-11-23
NO20015912D0 (no) 2001-12-03
TWI253447B (en) 2006-04-21
BRPI0011324B8 (pt) 2021-05-25
CN1353692A (zh) 2002-06-12
US20130231367A1 (en) 2013-09-05
GB9913083D0 (en) 1999-08-04
US20120077838A1 (en) 2012-03-29
US8658673B2 (en) 2014-02-25
AU5074500A (en) 2000-12-28
PT1183240E (pt) 2009-11-03
IL146578A0 (en) 2002-07-25
BE2010C011I2 (forum.php) 2019-05-21
WO2000075114A1 (en) 2000-12-14
US7820694B2 (en) 2010-10-26
US20100029705A1 (en) 2010-02-04
CA2375810A1 (en) 2000-12-14
IL146578A (en) 2007-05-15
NO2010014I1 (no) 2010-07-26
US8436017B2 (en) 2013-05-07
US8796307B2 (en) 2014-08-05
ZA200109931B (en) 2002-06-05
DE122010000009I1 (de) 2010-07-01
EP1183240B1 (en) 2009-08-19
CA2375810C (en) 2010-09-07
KR20020012590A (ko) 2002-02-16
NO322944B1 (no) 2006-12-18
PL352100A1 (en) 2003-07-28
CY1109604T1 (el) 2012-01-25
LU91651I2 (fr) 2010-04-19
HU227034B1 (en) 2010-05-28
ATE440083T1 (de) 2009-09-15
JP2003501417A (ja) 2003-01-14
MY126951A (en) 2006-11-30
CY2010003I1 (el) 2012-01-25
ES2402535T3 (es) 2013-05-06
NL300437I1 (nl) 2010-04-01
EP2332915A1 (en) 2011-06-15
HUP0201658A2 (en) 2002-08-28
NO20015912L (no) 2002-01-21
FR10C0006I2 (fr) 2011-04-01
RU2244709C2 (ru) 2005-01-20
US8067437B2 (en) 2011-11-29
US20140066478A1 (en) 2014-03-06
CY1114120T1 (el) 2016-07-27
NZ515669A (en) 2004-01-30
CZ20014301A3 (cs) 2002-03-13
PT2332915E (pt) 2013-04-11
BR0011324A (pt) 2002-03-05
US6878721B1 (en) 2005-04-12
JP3785365B2 (ja) 2006-06-14
MXPA01012474A (es) 2002-06-04
CO5170518A1 (es) 2002-06-27
PL198847B1 (pl) 2008-07-31
HK1154584A1 (en) 2012-04-27
DE122010000009I2 (de) 2012-08-09
US9040559B2 (en) 2015-05-26
DK2332915T3 (da) 2013-05-27
NO2010014I2 (forum.php) 2011-10-17

Similar Documents

Publication Publication Date Title
AR035548A1 (es) Compuestos organicos
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
AR061422A2 (es) Peptidos ciclicos selectivos, procedimiento de preparacion, composicion farmaceutica que los comprende, y uso de los mismos en la preparacion de medicamentos
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
PE20200665A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
PE20010964A1 (es) Derivados de tiazolilamida
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
CO4950611A1 (es) Derivados de 9-desoxo-9a-aza-9a-homoeritromicina ac-4 sustituidos
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
AR065863A1 (es) Derivados de imidazolidinona
PE20040373A1 (es) Composiciones herbicidas que comprenden derivados de isoxazolina
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
CO5080780A1 (es) Derivado de amida y antagonista de nociceptina
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
CO5631447A2 (es) Derivados de heteriarilamida benzocondesada de tieno- piridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos, y metodos pra su uso
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5060482A1 (es) Derivados terapeuticos de biarilo
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration